Cardiac repolarization abnormalities can be caused by a wide range of cardiac and non-cardiac compounds and may lead to the development of life-threatening Torsades de Pointes (TdP) ventricular arrhythmias. Drug-induced Torsades de Pointes is associated with unexpected and unexplained sudden cardiac deaths resulting in the withdrawal of several compounds in the past. To better understand the mechanism of such unexpected sudden cardiac deaths, the concept of repolarization reserve has recently emerged. According to this concept, pharmacological, congenital or acquired impairment of one type of transmembrane ion channel does not necessarily result in excessive repolarization changes because other repolarizing currents can take over and compensate. In this review, the major factors contributing to repolarization reserve are discussed in the context of their clinical significance in physiological and pathophysiological conditions including drug administration, genetic defects, heart failure, diabetes mellitus, gender, renal failure, hypokalaemia, hypothyroidism and athletes' sudden deaths. In addition, pharmacological support of repolarization reserve as a possible therapeutic option is discussed. Some methods for the quantitative estimation of repolarization reserve are also recommended. It is concluded that repolarization reserve should be considered by safety pharmacologists to better understand, predict and prevent previously unexplained drug-induced sudden cardiac deaths.
AbbreviationsAPD, action potential duration; ATP, adenosine triphosphate; ATX II, Anemonia sulcata toxin; cAMP, 3′-5′-cyclic adenosine monophosphate; DAD, delayed afterdepolarization; EAD, early afterdepolarization; ERP, effective refractory period; ICa,L, L-type inward calcium current; IKr, rapid delayed rectifier potassium current; IKs, slow delayed rectifier potassium current; INa, inward sodium current; Ito, transient outward potassium current; LQT1, long QT syndrome 1; LQT2, long QT syndrome 2; LQT3, long QT syndrome 3; LQT7, long QT syndrome 7; LQTS, long QT syndromes; miRNA, micro ribonucleic acid; NCX, Na + -Ca 2+ exchanger; PKA, protein kinase A; PKC, protein kinase C; TdP, Torsades de Pointes
IntroductionIt is well known that certain antiarrhythmic drugs induce life-threatening Torsades de Pointes (TdP) arrhythmia in 3-5% of patients. This was not considered particularly surprising because the drugs in question were expected to affect cardiac transmembrane ion channels and the electrophysiological properties of the heart as part of their therapeutic effect. Recently, however, there has been increasing concern about TdP arrhythmia and sudden death caused by noncardiac drugs. The incidence of TdP induced by non-cardiac drugs is usually low (less than 1:10 000 or 1:100 000).
BJPBritish Journal of Pharmacology DOI:10.1111DOI:10. /j.1476DOI:10. -5381.2011 14 British Journal of Pharmacology (2011) However, several of them including astemizole, cisapride, grepafloxacin, terfenadine, terolidine have been withdrawn from the market due to the...